SonyoShinMD

Oncology • Bridgewater, NJ

Physician

Join to view full profile

Dr. Shin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shin's full profile

Already have an account?

Office
1125 Route 22
Ste 270
Bridgewater, NJ 08807
Phone+1 908-947-7017

Fax+1 908-947-7018

Education & Training

East Tennessee State University/Quillen College of MedicineFellowship, Medical Oncology, 2007 - 2009
Lincoln Medical and Mental Health CenterResidency, Internal Medicine, 2001 - 2004
Ewha Women's University College of MedicineClass of 1998

Certifications & Licensure

NJ State Medical License 2009 - 2025
PA State Medical License 2009 - 2024
NY State Medical License 2006 - 2012
TX State Medical License 2006 - 2008
American Board of Internal Medicine Medical Oncology

Clinical Trials

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
Active, not recruiting
Phase 3
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) Start of enrollment: 2015 Feb 11
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

20 citations
Activator Protein-1 Has an Essential Role in Pancreatic Cancer Cells and Is Regulated by a Novel Akt-Mediated Mechanism
Sonyo Shin, Takayuki Asano, Yixin Yao, Ronghua Zhang, Francois Xavier Claret
Molecular Cancer Research. 2009-05-01
18 citations
Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells.
X Sui, Sonyo Shin, Ruo Dan Zhang, Pervez F. Firozi, L Yang
Oncogene. 2009-02-05
39 citations
Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells
Takayuki Asano, Yixin Yao, Sonyo Shin, James A. McCubrey, James L. Abbruzzese
Cancer Research. 2005-10-15